info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Inhaled Corticosteroid Device Market, by Types of Steroid Inhalers (Beclomethasone Dipropionate, Budesonide, Fluticasone, Mometasone, and Others), by Application (Asthma, COPD, and Others), by End-Users (Hospitals and Others) – Forecast Till 2032


ID: MRFR/MED/4953-HCR | 100 Pages | Author: Kinjoll Dey| November 2024

Inhaler Corticosteroid Device Market Overview


Inhaled Corticosteroid Device Market Size was valued at USD 0.48 Billion in 2023. The Inhaled Corticosteroid Device industry is projected to grow from USD 0.56 Billion in 2024 to USD 0.98 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.11% during the forecast period (2024 - 2032).


Asthma is a disease of the entire respiratory tract, including large, intermediate and small airways. Asthma led to inflammation and obstruction of respiratory tract. Patients have various treatment options for asthma, particularly for young and elderly patients. Hence this has led to significant interest on the part of the inhaler device which is easy to use. 


Inhaled corticosteroid is the most commonly used tool for the treatment of asthma. As with increasing pollution and increasing incidences of asthma, many companies are engaged in the development of new inhaler corticosteroid devices. Hence this factor is responsible for the growth of the inhaled corticosteroid device market.


However, the high cost of treatment, misuse of funding and lack of awareness are some of the factors which are hampering the growth of the market during the forecast period.


Inhaled Corticosteroid Device Market Segmentation


The inhaler corticosteroid device market is segmented into types of steroid inhalers, applications, and end-users. 


Based on types of steroid inhaler the market is segmented into beclomethasone dipropionate, budesonide, fluticasone inhaler powder, mometasone. 


On the basis of application, inhaler corticosteroid device market is segmented into asthma and COPD (chronic obstructive pulmonary disease), and other respiratory diseases. 


Based on end-user the market is segmented into hospitals, clinics, and respiratory care centers.  


Inhaled Corticosteroid Device Market Key Players


Some of the key players in the inhaler corticosteroid device market are: 



  • Plumage Therapeutics LLP

  • Pearl Therapeutic Inc

  • Teijin LTD

  • Glaxo’s Advair

  • LIYEN, Inc

  • Amgen Inc

  • Kos Pharmaceutical, Inc

  • Teva Pharmaceutical 


Inhaled Corticosteroid Device Market Regional Analysis


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The inhaler corticosteroid device market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. 


The European inhaler corticosteroid device market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  


The inhaler corticosteroid device market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The inhaler corticosteroid device market in the Middle East and Africa has been segmented into the Middle East and Africa.


In terms of market value, North America will dominate the inhaler corticosteroid device market during the forecast period. Increasing incidences of life-threatening illness such as chronic obstructive pulmonary disease, asthma and many more are some of the factors which are responsible for the growth of the market during the forecast period. The European market is expected to be the second-largest inhaler corticosteroid device market. 


The market growth in this region can be attributed to government funding and support of the healthcare sector coupled with increasing research and development. Moreover, a growing patient for asthma worldwide, increasing number of qualified physicians for inhaler corticosteroid device center and expanding aging demographics are some of the factors responsible for the rise in inhaler corticosteroid device market. 


Asia-Pacific is expected to be the fastest-growing market during the forecast period owing to the increasing prevalence of asthma, rising investments in healthcare, increasing geriatric population, and expansions by market players in the region. Asia-Pacific is giving the strong competition in the inhaler corticosteroid device market by producing a cost-effective treatment that is high in demand in local as well as in the global market. 


The market in the Middle East and Africa is expected to account for the smallest share in the inhaler corticosteroid device market due to the underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.


Market of Inhaler Corticosteroid Device, by Steroid Inhaler Types



  • Beclomethasone Dipropionate

  • Budesonide

  • Fluticasone Inhaler Powder

  • Mometasone


Market of Inhaler Corticosteroid Device, by Application



  • Asthma

  • COPD (Chronic Obstructive Pulmonary Disease)

  • Others


Market of Inhaler Corticosteroid Device, by End-User



  • Hospitals and Clinics

  • Academic and Research Institutes

  • Respiratory Care Center


Market of Inhaler Corticosteroid Device, by Region


Americas



  • North America

  • US

  • Canada

  • South America


Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe


Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific


Middle East & Africa



  • Middle East

  • Africa


Intended Audience



  • Hospitals and clinics

  • Laboratories and associations

  • Healthcare providers

  • Medical device manufacturers

  • Research institutes and academic centers

  • Government associations

  • Market research and consulting

Report Attribute/Metric Details
Market Size USD 0.98 Billion by 2032
CAGR 8.11% (2024-2032)
Base Year   2023
Forecast Period   2024 - 2032
Historical Data   2021
Forecast Units   Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Types, end user, Region
Geographies Covered America, Europe, Asia Pacific, Middle East and Africa
Key Vendors Plumage Therapeutics LLP, Pearl Therapeutic Inc, Teijin LTD, Glaxo’s Advair, LIYEN, Inc, Amgen Inc, Kos Pharmaceutical, Inc, and Teva Pharmaceutical


Frequently Asked Questions (FAQ) :

The projected CAGR would be 8.11% for the inhaled corticosteroid device market.

The inhaled corticosteroid device market would face challenges in the form of high treatment costs, funding complications, and lack of awareness.

The types are budesonide, fluticasone inhaler powder, beclomethasone dipropionate, and mometasone.

The players are Pearl Therapeutics Inc, Kos Pharmaceutical, Inc, Plumage Therapeutics LLP, Glaxo’s Advair, Teijin LTD, Amgen Inc, LIYEN, Inc, and Teva Pharmaceutical.

The North American market would lead the global charge.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.